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Introduction: In 2012, the Systemic Lupus International Collaborating Clinics (SLICC) network presented a new set
of criteria (SLICC-12) to classify systemic lupus erythematosus (SLE). The present study is the first to evaluate the
performance of SLICC-12 in an adult European study population. Thus, SLICC-12 criteria were applied to confirmed
SLE cases in our regional SLE register as well as to individuals with a fair suspicion of systemic autoimmune disease
who were referred to rheumatology specialists at our unit.
Methods: We included 243 confirmed SLE patients who met the 1982 American College of Rheumatology (ACR-82)
classification criteria and/or the Fries ‘diagnostic principle’ (presence of antinuclear antibodies on at least one
occasion plus involvement of at least two defined organ systems) and 55 controls with possible systemic
autoimmune disease, including the presence of any SLE-related autoantibody.
Results: SLICC-12 showed a diagnostic sensitivity of 94% (95% confidence interval (CI), 0.90 to 0.96) compared with
90% (95% CI, 0.85 to 0.93) for the updated set of ACR criteria from 1997 (ACR-97), whereas ACR-82 failed to identify
every fifth true SLE case. However, the disease specificity of SLICC-12 reached only 74% (95% CI, 0.60 to 0.84) and
did not change much when involvement of at least two different organs was required as an indicator of systemic
disease. In addition, SLICC-12 misclassified more of the controls compared to ACR-82, ACR-97 and Fries.
Conclusions: Establishing a standard definition of SLE continues to challenge lupus researchers and clinicians. We
confirm that SLICC-12 has advantages with regard to diagnostic sensitivity, whereas we found the diagnostic
specificity to be surprisingly low. To accomplish increased sensitivity and specificity figures, a combination of criteria
sets for clinical SLE studies should be considered.Introduction
Symptoms related to systemic lupus erythematosus (SLE)
are numerous and highly variable. Whereas common
manifestations in joints, skin, mucous membranes, bone
marrow and kidneys are usually rather easily identified,
more subtle manifestations, such as neurological symp-
toms, may remain unrecognized or not judged to be re-
lated to SLE [1]. The disease course is unpredictable, with
episodes of flares and remissions, sometimes leading to
permanent organ damage and preterm death [2].* Correspondence: christopher.sjowall@liu.se
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stated.The profound heterogeneity of SLE causes problems re-
garding diagnostic accuracy in clinical practice and par-
ticularly in clinical research. Over the years, great efforts
have been made to establish meaningful sets of criteria to
scientifically classify and differentiate the many rheumatic
diseases. The American College of Rheumatology (ACR)
conducted the first SLE criteria in 1971, but these criteria
did not gain much attention [3,4]. By contrast, the revised
and validated ACR classification criteria of 1982 (ACR-82)
have been used extensively, although concerns were raised
early that they were too conservative and outmoded [5].
For instance, ACR-82 does not consider lowered comple-
ment levels, but includes a positive lupus erythematosus
(LE) cell test as well as a positive Wassermann reactionis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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tenth criterion (immunologic disorder), although these
tests are in general regarded as obsolete [6]. In addition,
ACR-82 does not consider many of the common cutane-
ous and neurological manifestations found in SLE and
does not accept biopsy-proven lupus nephritis (LN) as
SLE in the absence of other manifestations. As an alterna-
tive, Fries and Holman’s diagnostic principle has been
found to be clinically useful. It is based on the presence of
antinuclear antibodies (ANAs) on at least one occasion
plus signs of systemic disease with involvement of at least
two defined organ systems (including skin, joints, kidney,
serosa, blood, lungs and nervous system) [7,8]. One ap-
proach to modernizing the ACR criteria was made by
Hochberg in a letter to Arthritis & Rheumatism with the
suggestion of removing the LE cell item and replacing it
with lupus anticoagulant and anticardiolipin antibodies of
the immunoglobulin M (IgM) or IgG class [9]. Unfortu-
nately, validation of the proposed 1997 update of the ACR
criteria (ACR-97) was not performed until recently.
The Systemic Lupus International Collaborating Clinics
(SLICC) network, devoted to clinical research in SLE, pre-
sented a new set of classification criteria in 2012 (SLICC-12)
based on the evaluation of almost 1,400 patient scenar-
ios [10]. Their work included both a derivation and a
validation of the new set of criteria as well as of ACR-97.
The SLICC-12 criteria contain additional clinical and
immunological items. Fulfilment of four or more criteria
(including at least one clinical and one immunologic item)
of the eleven clinical and six immunologic items are re-
quired for an SLE diagnosis according to SLICC-12. An
important addition is that biopsy-proven LN in combin-
ation with the presence of ANAs and/or antibodies to
double-stranded DNA (anti-dsDNA) appears as a stand-
alone item that is accepted as SLE according to SLICC-12,
regardless of other organ manifestations. In the validation
set, the SLICC-12 criteria were noted to be more sensitive
but less specific than ACR-97, but they also resulted in
fewer misclassifications [10]. Although much indicates
that the SLICC-12 criteria will contribute to a higher sen-
sitivity for detecting SLE compared with previous classifi-
cation grounds, it is still unclear how much acceptance
they will receive.
The present study was undertaken to apply the SLICC-12
criteria and compare them with ACR-82, ACR-97 and Fries
and Holman’s diagnostic principle (hereinafter referred to as
‘Fries’), based on well-characterized SLE cases included in a
Swedish regional SLE register as well as on autoantibody-
positive individuals referred to our rheumatology unit on
the suspicion of systemic autoimmune disease. Inspired by
Fries and Holman, we also aimed to further stress the re-
quirements for SLICC-12 by demanding that an SLE diag-
nosis be based on involvement of at least two different
organ systems as an indicator of systemic disease [7].Methods
Confirmed systemic lupus erythematosus cases
A total of 243 patients with established (84%) or recent-
onset (16%) SLE (213 women and 30 men; mean age in
January 2014 was 52.8 years, ranging from ages 20 to 92)
were consecutively recruited to the prospective follow-up
programme KLURING (a Swedish acronym for ‘Clinical
Lupus Register in Northeastern Gothia’) at the Rheumatol-
ogy Clinic, Linköping University Hospital, Sweden, between
September 2008 and January 2014. The patient material
has previously been described in detail [11,12]. The follow-
ing criteria were used for entry into KLURING: (1) a clin-
ical SLE diagnosis based on a history of abnormal ANA
titres and at least two defined organ manifestations at the
time of diagnosis (Fries) and/or (2) meeting the ACR-82
criteria [6,7]. Of the 58 patients who met the ACR-82 item
for ‘renal disorder’, 48 (83%) had undergone renal biopsy
for confirmation of suspected LN. Further characteristics of
the patients with SLE are given in Table 1.
Controls
A total of 55 individuals (48 women and 7 men; mean
age in January 2014 of 49.0 years, ranging from ages 18
to 85) who had been referred to the Rheumatology
Clinic, Linköping University Hospital on the suspicion of
systemic autoimmune disease were included as control
cases. All individuals had at least one immunologic abnor-
mality on the basis of any of the following: positive ANA
by immunofluorescence microscopy (IF-ANA); or the
presence of any of the antibodies against extractable nu-
clear antigens (ENAs); i.e. SSA, SSB, Sm, small nuclear
ribonucleic proteins, Scl-70 or Jo-1; or IgM and/or IgG
class antibodies against phospholipid (PL)-related antigens
(cardiolipin and/or β2-glycoprotein-1) or a positive test for
lupus anticoagulant; or signs of plasma complement con-
sumption. Two of the controls had undergone renal biopsy
as a confirmation of suspected LN. Further characteristics
of the control cases are presented in Tables 1 and 2.
Laboratory analyses
IgG class ANAs were analysed by indirect IF microscopy
using multispot slides with fixed HEp-2 cells (Immuno-
Concepts, Sacramento, CA, USA) as previously de-
scribed [11]. The cutoff level for a positive ANA test was
set at a serum dilution of 1:200, corresponding to above
the 95th percentile among 150 healthy female blood do-
nors. Microscope slides with fixed Crithidia luciliae
(ImmunoConcepts) and fluorescein isothiocyanate
(FITC)–conjugated γ-chain-specific anti-human IgG as
the detection antibody (DAKO, Glostrup, Denmark) were
used to analyse IgG class anti-dsDNA antibodies by IF mi-
croscopy with cutoff at serum dilution 1:10, corresponding
to above the 99th percentile among 100 healthy blood do-
nors (50 women, 50 men).
Table 1 Characteristics of the 243 included patients with confirmed systemic lupus erythematosusa
Characteristics All confirmed SLE cases (N = 243) ACR-82 (n = 197) Fries only (n = 46) ACR-82 vs. Fries P-values
Mean (Range) Mean (Range) Mean (Range)
Fulfilled ACR-82 criteria, n 4.6 (3 to 9) 5.0 (4 to 9) 3.0 (3 to 3) <0.0001b
SLICC/ACR damage index 1.6 (0 to 9) 1.7 (0 to 9) 1.2 (0 to 7) 0.25b
Disease duration, yr 15.1 (0 to 52) 15.6 (0 to 52) 12.9 (1 to 40) 0.18b
Age, yr 52.8 (20 to 92) 52.2 (20 to 92) 55.6 (20 to 82) 0.20b
Female sex, % 87.7 87.5 89.1 0.74b
Caucasians, % 92.2 91.4 95.7 0.33b
Clinical manifestations (%)
Acute cutaneous lupus 65.8 71.6 41.3 <0.0001c
Chronic cutaneous lupus 15.2 17.8 4.3 0.023c
Photosensitivity 50.6 56.3 26.1 0.0002c
Nonscarring alopecia 21.4 22.3 17.4 0.46c
Oral ulcers 11.1 12.7 4.3 0.11c
Arthritis 75.7 76.1 73.9 0.75c
Pleuritis 37.9 39.1 32.6 0.41c
Pericarditis 14.8 15.2 13.0 0.71c
Renal disorder 23.9 28.9 2.2 <0.0001c
Biopsy-proven lupus nephritis 19.8 23.9 2.2 0.0009c
Neurologic disorder (ACR-82) 4.9 5.6 2.2 0.34c
Neurologic disorder (SLICC-12) 10.7 12.7 2.2 0.038c
Haemolytic anaemia 4.9 6.1 0 0.086c
Leukopenia 29.2 33.0 13.0 0.0074c
Lymphopenia 29.2 34.0 8.7 0.0007c
Thrombocytopenia 11.5 12.7 6.5 0.24c
Immunologic criteria (%)
Antinuclear antibody 98.8 98.5 100.0 0.40c
Anti-dsDNA 45.3 53.3 10.9 <0.0001c
Anti-Sm 8.2 9.1 4.3 0.29c
Lupus anticoagulantd 36.3 34.3 43.6 0.097c
Anti-cardiolipine 28.5 30.7 19.5 0.23c
Anti-β2-glycoprotein-1f 29.2 30.0 25.9 0.80c
Low complement 47.3 51.3 30.4 0.011c
Direct Coombs testg 51.3 58.1 29.6 0.25c
aACR-82, American College of Rheumatology 1982 criteria; Anti-dsDNA, Antibodies to double-stranded DNA; Anti-Sm, Anti-Smith antibody; Fries, Fries and Holman’s
diagnostic principle [7]; SLE, Systemic lupus erythematosus; SLICC-12, 2012 Systemic Lupus International Collaborating Clinics criteria. bP-values based on Mann–Whitney
U test. cP-values based on χ2 test. Criteria were tested on any occasion in d182 of 243 patients, e207 of 243 patients, f137 of 243 patients and g113 of 243 patients.
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technique as previously described [11]. To qualify as a
positive test for anti-Sm antibody, confirmation by
double radial immunodiffusion in gel (ImmunoCon-
cepts) was always required. Lupus anticoagulant was
performed by the dilute Russell’s viper venom test. De-
tection of antibodies against cardiolipin and β2-glyco-
protein-1 were performed using an enzyme-linked
immunosorbent assay (Orgentec Diagnostika, Mainz,
Germany) and/or by a fluorescence immunoassay (ELiA;Phadia, Uppsala, Sweden). Only IgM and IgG class anti-
bodies against cardiolipin and β2-glycoprotein-1 (as in-
cluded in the ACR-97 criteria) were analysed, whereas
analysis of IgA (as included in the SLICC-12 criteria) was
not performed. Levels of complement proteins C3 and C4
were measured by nephelometry in fresh frozen plasma
samples, and classical complement function was assessed
by a haemolytic assay. The direct Coombs test was
analysed by haemolysis in gel (BIO-RAD Laboratories,
Hercules, CA, USA).
Table 2 Characteristics of the 55 included control casesa
Characteristics Control cases (n = 55)
Mean (range)
Fulfilled ACR-82 criteria, n 2.2 (1 to 3)
Age, yr 49.0 (18 to 85)
Female sex, % 87.3
Clinical manifestations (%)
Acute cutaneous lupus 34.5








Biopsy-proven lupus nephritis 3.6
Neurologic disorder (ACR-82) 0













Direct Coombs testc 13.6
aACR-82, American College of Rheumatology 1982 criteria; Anti-dsDNA, Antibodies
to double-stranded DNA; Anti-Sm, Anti-Smith antibody; SLICC-12, 2012 Systemic
Lupus International Collaborating Clinics criteria. Criteria were tested on any
occasion in b37 of 55 cases and c44 of 55 cases.
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were crucial to determining which set(s) of criteria were
met, all analyses regarding immunologic criteria were
analysed (further specified in Tables 1 and 2).
Statistics
Clinical and immunologic criteria were described by
their proportions (%). Differences between cases meet-
ing ACR-82 and Fries only were examined by Mann–
Whitney U tests or χ2 tests of homogeneity. Classifications
of participants based on Fries, ACR-82, ACR-97, SLICC-
12 and SLICC-12 with a requirement for involvement of
at least two organ systems for SLE diagnosis (SLICC-12:2),separately and in combinations, were examined. Sensitivity
and specificity figures were calculated for the confirmed
cases (n = 243) and the controls (n = 55). Positive predict-
ive value (PPV) and negative predictive value (NPV) were
calculated as the average PPV and NPV based on a pro-
cedure where the controls (n = 55) were combined 1 mil-
lion times with a random sample of the same size (n = 55)
from the confirmed cases. The Wilson score method was
used to calculate 95% confidence intervals (CIs) [13].
Ethical considerations
Oral and written informed consent was obtained from
all subjects. The study protocol was approved by the
Linköping University Ethical Review Board, Sweden
(M75-08/2008).
Results
As indicated in Table 1, 197 (81%) of 243 confirmed SLE
cases fulfilled the ACR-82 criteria, whereas 46 (19%) met
the Fries criteria only. The presence of either IgM or IgG
class antibodies against cardiolipin or β2-glycoprotein-1
and/or a positive lupus anticoagulant test (not classified as
an immunologic criterion according to ACR-82) was
found in 23 (50%) of the cases meeting the Fries criteria
alone. Of the 243 confirmed cases, 220 (91%) fulfilled the
ACR-97 criteria.
In addition to the number of fulfilled ACR-82 criteria,
significant differences between the ACR-82 and Fries
groups were found for certain manifestations related to
skin, renal, neurologic, hematologic and immunologic
items. On average, the 55 controls met significantly
fewer ACR-82 criteria than the confirmed cases (P <
0.0001). The slightly younger average age of the controls
(49 years; age range, 18 to 85) compared to confirmed
cases (52.8 years; age range, 20 to 92) was not statisti-
cally significant (P = 0.14). Also, the female predomin-
ance was similar among cases (87.7%) and controls
(87.3%).
As demonstrated in Figure 1A, SLICC-12 identified
228 (94%) of 243 confirmed cases. To emphasize the sys-
temic nature of SLE, we further increased the require-
ments for SLICC-12 by demanding involvement of at
least two organ systems for SLE diagnosis (SLICC-12:2),
but still with the exception of biopsy-proven LN (in
combination with ANA/anti-dsDNA), which was consid-
ered a stand-alone item. As illustrated in Figure 1B,
SLICC-12:2 identified 216 (89%) of 243 confirmed cases.
Thus, 12 confirmed cases identified by SLICC-12 (5.2%)
had involvement of only one organ system together with
fulfilment of immunologic criteria.
The 55 controls (Table 2) eventually received the follow-
ing diagnoses: undifferentiated connective tissue disease
(UCTD) (n = 13) [14]; primary Sjögren’s syndrome (n = 10);
antiphospholipid syndrome (APS) (n = 7); rheumatoid
Figure 1 Venn diagrams illustrating the distribution of confirmed systemic lupus erythematosus cases and controls for each separate
classification ground. Venn diagrams demonstrate the distribution of the 243 confirmed (SLE) cases identified (A) by the 1982 American College
of Rheumatology (ACR-82) criteria (blue), Fries (green) and SLICC-12 (pink), and (B) by ACR-82 criteria (blue), Fries and Holman diagnostic principle
(Fries [7]) (green) and the 2012 Systemic Lupus International Collaborating Clinics criteria with SLICC-12 with a requirement for involvement of at
least two organ systems for SLE diagnosis (SLICC-12:2) (red) (that is, with the requirement to involve at least two different organ systems). The 55
controls identified (C) by ACR-82 (blue), Fries (green) and SLICC-12 (pink) and (D) by ACR-82 (blue), Fries (green) and SLICC-12:2 (red). Controls
who did not meet any of the classification grounds are indicated in black.
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3); SLE (n = 2); adult-onset Still’s disease (n = 1); polymyosi-
tis (n = 1); systemic sclerosis with primary biliary cirrho-
sis (n = 1); mixed connective tissue disease (n = 1);
pyogenic arthritis, pyoderma gangrenosum and acne
syndrome (n = 1); renal infarction (n = 1); multiple scler-
osis (n = 1); psoriatic arthritis (n = 1); unspecified arthritis
(n = 1); and recurrent pleuritis (n = 1).
The Fries, ACR-82 and ACR-97 criteria all failed to
identify the two true SLE cases with biopsy-proven LN
amongst the controls, whereas these cases were captured
by the SLICC-12 criteria (Figure 1C). On the other hand,
SLICC-12 incorrectly classified 14, Fries 10 and ACR-97
4 non-SLE cases as SLE. These misclassified cases were
primarily patients deemed to have APS, RA, UCTD or
primary Sjögren’s syndrome. On the basis of SLICC-12:2, 12 of the controls still were misclassified as SLE
(Figure 1D).
On the basis of combined data from the confirmed
cases and controls (n = 298), sensitivity, specificity, PPVs
and NPVs were calculated for each separate classification
ground, as well as for some combinations (Table 3).
ACR-82 was found to have very high disease specificity,
whereas the sensitivity was 80% (95% CI, 0.75 to 0.85).
ACR-97 reached both sensitivity and specificity of
around 90%. Although the sensitivity was even higher
with SLICC-12, at 94% (95% CI 0.90 to 0.96), the specifi-
city was low, at 74% (95% CI, 0.60 to 0.84), and did not
increase appreciably with the use of SLICC-12:2 (77%;
95% CI, 0.64 to 0.87). The diagnostic sensitivity of Fries
was 98% (95% CI, 0.96 to 1.0), and the diagnostic specifi-
city was 83% (95% CI, 0.70 to 0.91). Many of the
Table 3 Sensitivity, specificity and positive and negative predictive values for each separate classification ground, as
well as for some combinationsa
Sensitivity Specificity PPV NPV
Fries 0.98 (0.95 to 0.99) 0.81 (0.68 to 0.90) 0.84 (0.75 to 0.94) 0.94 (0.86 to 1.00)
ACR-82 0.80 (0.75 to 0.85) 1 (0.91 to 1.00) 1 (0.93 to 1.00) 0.81 (0.71 to 0.91)
ACR-97 0.90 (0.85 to 0.93) 0.92 (0.81 to 0.98) 0.93 (0.84 to 1.00) 0.87 (0.78 to 0.97)
SLICC-12 0.94 (0.90 to 0.96) 0.74 (0.60 to 0.84) 0.79 (0.70 to 0.89) 0.92 (0.83 to 1.00)
SLICC-12:2 0.89 (0.84 to 0.92) 0.77 (0.64 to 0.87) 0.81 (0.71 to 0.91) 0.87 (0.76 to 0.98)
Fries and/or ACR-82 0.99 (0.97 to 1.00) 0.81 (0.68 to 0.90) 0.85 (0.75 to 0.94) 0.96 (0.87 to 1.00)
Fries and/or ACR-97 1 (0.97 to 1.00) 0.81 (0.68 to 0.90) 0.85 (0.75 to 0.94) 0.96 (0.87 to 1.00)
Fries and/or SLICC-12 0.99 (0.97 to 1.00) 0.68 (0.54 to 0.79) 0.77 (0.67 to 0.86) 0.99 (0.91 to 1.00)
ACR-82 and/or SLICC-12 0.96 (0.92 to 0.98) 0.74 (0.60 to 0.84) 0.80 (0.70 to 0.89) 0.95 (0.86 to 1.00)
ACR-82 and/or SLICC-12:2 0.93 (0.90 to 0.96) 0.77 (0.64 to 0.87) 0.82 (0.72 to 0.91) 0.92 (0.82 to 1.00)
At least one of Fries, ACR-82 or SLICC-12 1 (0.98 to 1.00) 0.68 (0.54 to 0.79) 0.77 (0.67 to 0.87) 1 (0.92 to 1.00)
At least one of Fries, ACR-82 or SLICC-12:2 1 (0.98 to 1.00) 0.72 (0.58 to 0.82) 0.79 (0.70 to 0.89) 1 (0.92 to 1.00)
(Fries + ACR-82) and/or (Fries + SLICC-12) 0.94 (0.90 to 0.96) 0.87 (0.75 to 0.94) 0.88 (0.79 to 0.97) 0.90 (0.82 to 0.99)
aACR-82, American College of Rheumatology 1982 criteria; ACR-97, American College of Rheumatology 1997 criteria; Fries, Fries and Holman’s diagnostic principle
[7]; NPV, Negative predictive value; PPV, Positive predictive value; SLICC-12, 2012 Systemic Lupus International Collaborating Clinics criteria; SLICC-12:2, SLICC-12
criteria with a requirement for involvement of at least two organ systems for SLE diagnosis. Data are presented with 95% confidence intervals in parentheses.
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figures, as indicated by the fact that most CIs over-
lapped. The theoretical combination of ‘Fries and ACR-
82’ and/or ‘Fries and SLICC-12’ performed best with
regard to diagnostic sensitivity and specificity. ‘ACR-82
and/or Fries’, as used in our regional register KLURING,
resulted in sensitivity and specificity figures virtually
similar to those for ‘ACR-82 and/or SLICC-12’ and ‘Fries
and/or ACR-97’, respectively. In patients with newly
diagnosed (0 to 4 years) SLE, the sensitivity appeared
to be slightly better with SLICC-12 than with ACR-97,
and it was obviously better than ACR-82 (Table 4).
Discussion
Classification criteria were originally created to describe
and characterize patient populations primarily in re-
search settings with the pursuit of a high specificity for
established disease [15]. Although the 1982 ACR set of
classification criteria was never intended to be diagnos-
tic, many clinicians have leaned against these as a diag-
nostic tool. However, as pointed out by Bertsias et al.,
this procedure is beset with certain caveats regarding
both over- and underestimation [16]. Thus, it is import-
ant to underline that disease management decisions
must often be made even if the classification criteria are
not strictly met.
In the present study, we aimed to evaluate the per-
formance of SLICC-12 in a ‘real-life’ clinical setting.
Hence, the SLICC-12 criteria were applied to confirmed
cases in our regional SLE register, as well as to individ-
uals who were referred to rheumatology specialists on
the basis of a fair suspicion of systemic autoimmunedisease, including the presence of any SLE-related auto-
antibody. Fulfilment of either the Fries and/or ACR-82
criteria permitted entry of these patients into the KLUR-
ING cohort, and it could thus be argued that this would
favour these criteria with regard to sensitivity and speci-
ficity in this evaluation. However, in addition to also in-
cluding ACR-97 in the comparisons, we believe that the
present study has additional benefits. For instance, the
controls did not have established rheumatological diag-
noses, a situation that obviously well reflects the real-life
scenario with diagnostic dilemmas. Our main findings
are that (1) SLICC-12 has high diagnostic sensitivity
(particularly in patients with recent-onset disease), which
is in line with the results of others [10,17]; and (2) ACR-
82 fails to identify every fifth true SLE case. The latter
finding confirms the results of a Norwegian study based
on 346 patients with connective tissue disease [18]. To
our surprise, however, the disease specificity for SLICC-
12 was as low as 74% and did not change much with the
addition of a requirement that at least two different
organ systems must be involved. SLICC-12 misclassified
14 of the 55 controls, compared to 10 using Fries, 4
using ACR-97 and none using ACR-82.
Three studies resembling our present study have re-
cently been published. Sag et al. presented data from
three European paediatric lupus centres regarding the
performance of SLICC-12 in comparison with ACR-97
in 154 SLE cases and 123 controls in whom ANA ana-
lysis within the diagnostic workup was deemed necessary
by the attending physician [19]. Control cases with
established disease were selected (juvenile idiopathic
arthritis was the most common diagnosis), whereas none
Table 4 Sensitivity for each separate classification ground for groups with different disease durationsa
0 to 4 years (n = 33) 5 to 9 years (n = 53) 10 to 14 years (n = 47) 15 to 19 years (n = 43) ≥20 years (n = 69)
Fries 0.94 (0.80 to 1.00) 0.96 (0.86 to 1.00) 0.96 (0.85 to 1.00) 0.91 (0.78 to 0.98) 0.96 (0.87 to 0.99)
ACR-82 0.60 (0.44 to 0.75) 0.89 (0.77 to 0.96) 0.76 (0.62 to 0.86) 0.69 (0.54 to 0.81) 0.86 (0.75 to 0.92)
ACR-97 0.82 (0.65 to 0.92) 0.94 (0.84 to 0.99) 0.91 (0.79 to 0.98) 0.86 (0.72 to 0.94) 0.91 (0.82 to 0.97)
SLICC-12 0.89 (0.73 to 0.97) 0.89 (0.77 to 0.96) 0.88 (0.75 to 0.95) 0.84 (0.71 to 0.93) 0.97 (0.89 to 1.00)
SLICC-12:2 0.80 (0.64 to 0.91) 0.84 (0.71 to 0.92) 0.84 (0.70 to 0.92) 0.80 (0.66 to 0.90) 0.94 (0.85 to 0.98)
aACR-82, American College of Rheumatology 1982 criteria; ACR-97, American College of Rheumatology 1997 criteria; Fries, Fries and Holman’s diagnostic principle
[7]; SLICC-12, 2012 Systemic Lupus International Collaborating Clinics criteria; SLICC-12:2, SLICC-12 criteria with a requirement for involvement of at least two organ
systems for SLE diagnosis. Data are presented with 95% confidence intervals in parentheses. The groups are based on the 243 patients with confirmed systemic
lupus erythematosus plus the 2 controls with biopsy-proven lupus nephritis.
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12 was more sensitive and resulted in fewer misclassifi-
cations, whereas ACR-97 was more specific. Amezcua-
Guerra et al. performed a chart review of 100 patients
with a clinical diagnosis of SLE and 100 patients with
established rheumatic disease, mainly RA [17]. They
concluded that ACR-97 and SLICC-12 performed simi-
larly well with regard to sensitivity as well as specificity.
Pons-Estel et al. applied SLICC-12 in two multiethnic
SLE cohorts and evaluated whether SLICC-12 would
allow earlier classification of SLE, particularly in patients
with LN, compared to ACR-97 [20]. Even though the in-
terpretation was hampered by the fact that the two co-
horts did not have similar entry criteria, the authors
concluded that earlier classification of SLE with or with-
out renal involvement was possible using SLICC-12, al-
though it was not as clear in the LUMINA group as in
the GLADEL cohort.
Contrary to the studies referred to above, the patients
included in our present study were recruited from a
single rheumatology unit and evaluated clinically and
followed with regard to disease phenotype, activity and
organ damage for a long period of time by a very limited
number of rheumatology specialists [11,21]. In addition,
all serological tests were analysed at the same accredited
laboratory. Among the confirmed cases, 92% were
Caucasians, which is fairly representative of a European
SLE population [22]. The number of fulfilled ACR-82
criteria among the confirmed SLE cases (mean, 4.6) may
appear low, but it is explained by the fact that our centre
is the only one that diagnoses and treats adult patients
with SLE in the catchment area of Linköping, Sweden.
This implies that we have no bias due to selection of se-
vere SLE cases. Thus, we can conclude that about 96%
of the expected SLE cases and 99% of all known adult
SLE cases were included in the study [23]. Consequently,
this means that our unit takes care of the whole adult
SLE spectrum, from uncomplicated cases with quiescent
disease and skin and/or joint involvement to severely ill
individuals with full-blown multisystemic disease.
A limitation of the study is the low number of con-
trols. However, to compensate for this, we provide 95%CIs to indicate part of the uncertainty. The procedure of
using 1 million random samples of the same size as the
controls from the confirmed cases provided the best pos-
sible estimates of PPV and NPV, whereas the 95% CIs
could still be based upon the appropriate number of pa-
tients (n = 110) to indicate the level of uncertainty (that is,
wide CIs). Another possible limitation is that IgA class
antibodies against PL-related antigens, which should be
regarded according to SLICC-12, were not analysed. Thus,
it is possible that the addition of data on IgA antibodies to
cardiolipin and/or β2-glycoprotein-1 could have increased
the SLICC-12 sensitivity figures. However, to our opinion,
more careful evaluations of these IgA class antibody tests
are still required before their benefits can be advocated for
clinical practice [24].
SLICC-12 was elaborated in order to achieve an up-
dated, relevant and meaningful set of SLE criteria with
high sensitivity. One important distinction from ACR-82
and ACR-97 is that SLICC-12 demands at least one im-
munologic criterion, prohibiting the SLE diagnosis from
being based solely on clinical manifestations [10]. At the
same time, because this may increase the diagnostic speci-
ficity for SLE, it could also have opposite effects. For in-
stance, and as demonstrated here, patients with APS
(without SLE) commonly present with thrombocytopenia
and complement consumption in combination with ANA
and antibodies against PL-related antigens, and would
thus incorrectly be classified as SLE according to SLICC-
12 criteria. Another challenge, including several laboratory
items in the classification grounds, is the choice of
methods and definition of accurate cutoff levels. In our
view, it is unfortunate that the SLICC group refrained
from postulating that IF microscopy should remain the
reference method for ANA analysis, referring to an ‘abnor-
mal titre’ (that is, a cutoff based on a reference population)
to qualify as a positive test in the new set of criteria [10].
Conclusions
This study is the first to evaluate the performance of
SLICC-12 in an adult European study population. We af-
firm that SLICC-12 has advantages with regard to diag-
nostic sensitivity in comparison with other classification
Ighe et al. Arthritis Research & Therapy  (2015) 17:3 Page 8 of 8grounds on the basis of our study of (1) patients in our re-
gional register with confirmed and well-characterized SLE
and (2) autoantibody-positive patients who had been re-
ferred to rheumatology specialists on the basis of a fair sus-
picion of systemic autoimmune disease. However, whereas
the sensitivity appeared to be superior with SLICC-12
compared with ACR-82 and ACR-97 (particularly in newly
diagnosed cases), the diagnostic specificity for SLICC-12
was surprisingly low. Thus, to realise the greatest sensitiv-
ity and specificity, a combination of criteria for clinical SLE
studies should be considered.
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